Resectable Biliary Tract Cancer
Conditions
Brief summary
This phase II trial studies how well gemcitabine, cisplatin, nab-paclitaxel and durvalumab work before surgery in treating participants with Biliary Tract Cancer. The international multicenter phase III clinical study TOPAZ-1 has confirmed that durvalumab combined with gemcitabine and cisplatin can bring survival benefits to advanced BTC. Drugs used in chemotherapy, such as nab-paclitaxel, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy and Durvalumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
DRUGCisplatin
25mg/m2；d1, 8, 21 d cycle
DRUGGemcitabine
1000mg/m2；d1, 8, 21 d cycle
DRUGNab-paclitaxel
100mg/m2；d1, 8, 21 d cycle
DRUGDurvalumab
1000mg；d1, 21 d cycle
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. The pathological diagnosis has confirmed biliary tract malignancy;pathological evidence may be obtained from biopsy/puncture, surgical resection specimens, or a formal pathology report. 2. Computed tomography (CT) or magnetic resonance imaging (MRI) shall be performed with high-quality cross-sectional imaging, and diagnosed as resectable high-risk biliary malignant tumors, limited to the liver, bile duct and/or regional lymph nodes (at least one of the following criteria must be met) : * T-stage ≥ Ib (Ib-IV) * Solitary lesion \> 5 cm * Multifocal tumors or satellite lesions present confined to the same lobe of the liver as the dominant lesion but still technically resectable * Presence of major vascular invasion but still technically resectable * Suspicious or involved regional lymph nodes (N1) * No distant extrahepatic disease (M0) 3. The patient's gender is not limited, and the age is 18-75 years old; Life expectancy\>3 months; 4. Within one week of enrollment, the ECOG PS score was 0 or 1; 5. No serious complications, such as hypertension, coronary heart disease and psychiatric history, and no serious allergic history; Non pregnancy and non lactation period; 6. The patient's organ and blood system functions meet the requirements: * Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L * Platelet count ≥ 100 × 10\^9/L * Hemoglobin ≥ 90 g/L * Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase ≤ 2.5 x ULN * Albumin ≥ 3g/dL * Creatinine ≤ 1.5 x ULN 7. The patient can understand and sign the informed consent form to participate in the trial study; can follow up with good compliance.
Exclusion criteria
1. Patients who received PD-1, PD-L1, PD-L2, CTLA-4 inhibitors before enrollment, or patients who directly received another stimulatory or co inhibitory T cell receptor (such as CTLA-4, CD137); 2. Used any other research drugs within 4 weeks before enrollment; 3. Any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism after hormone replacement therapy); Patients with childhood asthma who have completely alleviated and do not need any intervention or leukorrhea after adulthood can be included, but patients who need medical intervention with bronchodilators cannot be included; 4. With congenital or acquired immune deficiency, such as people infected with human immunodeficiency virus (HIV), active hepatitis B (HBV DNA 500IU/ml), hepatitis C (hepatitis C antibody is positive, and HCV-RNA is higher than the detection limit of the analytical method) or people with hepatitis B and hepatitis C co infection; 5. Severe infection (such as intravenous drip of antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first drug administration, or fever of unknown cause\>38.5 ° C occurred during screening/before the first drug administration; 6. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 7. Test drug allergy; 8. Suffering from uncontrollable mental illness; 9. Peripheral neuropathy of grade 2 or above according to CTCAE 4.0. In CTCAE 4.0, grade 2 sensory neuropathy is defined as "moderate symptoms; restriction of activities of daily living (ADL)"; 10. Occurrence of serious and/or uncontrollable diseases at the same time may affect participation in the study, such as unstable angina, myocardial infarction within 6 months, unstable symptomatic arrhythmia, symptomatic congestive heart failure, diabetes out of control, severe activity, uncontrollable infection after inadequate biliary drainage (such as tumor blocking the bile duct), or mental disease/social condition; 11. Pregnancy (positive pregnancy test) or lactation; 12. Diseases of central nervous system (CNS), except for brain metastasis treated. The treated brain metastatic tumor is defined as confirmed by clinical examination and brain imaging (MRI or CT) during the screening period, and there is no sign of progress or bleeding after treatment, and there is no need for continuous application of dexamethasone. Anticonvulsant drugs (stable dosage) are allowed. The treatment of brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; gamma knife, linear accelerator \[LINAC\] or equivalent) or a combination deemed appropriate by the treating doctor. Patients with central nervous system metastasis who underwent neurosurgical resection or brain biopsy within 3 months before the first day were excluded; 13. Other cancers in the past (within the past 5 years) or at the same time, excluding non melanoma skin cancer and carcinoma in situ; 14. History of allergy or hypersensitivity to any study drug; 15. Current abuse of alcohol or illicit drugs; 16. Unable or unwilling to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of completion of all preoperative and operative therapy | Up to 9 weeks after study start | Completion of all therapy rate will be recorded |
| Incidence of adverse events | Up to 1 years after study start | Will be monitored using method of Thall, Simon and Estey, and will be tabulated by the maximum reported Common Terminology Criteria for Adverse Events (CTCAE) grade. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response rate defined as the percentage of patients who will have complete response (CR), partial response (PR) or stable disease (SD) after the neoadjuvant therapy | Up to 9 weeks after study start | Will be evaluated according to Response Evaluation Criteria in Solid Tumor (RECIST). |
| Rate of R0 resection | Up to 9 weeks after study start | R0 resection is defined as no tumor remains at the cutting edge and no tumor cells remain at the cutting edge under the microscope |
| Recurrence-free survival (RFS) | Up to 1 years after study start | RFS is defined as the time between the date of surgery and the date of disease recurrence or death, whichever occurred first. If a patient did not have an event (i.e. disease recurrence or death) by the time of final analysis, patient will be censored at the last disease evaluation time. |
| Overall survival (OS) | Up to 1 years after study start | OS is defined as the time from date of neoadjuvant treatment start to the date of death from any cause or to the date of last follow-up if patients are alive. If a patient is alive by the time of final analysis, the patient will be censored at the last follow-up date. |
Countries
China
Contacts
CONTACTHuikai Li, M.D.
Outcome results
None listed